IP Library › Granted Patent US 12,269,896
Granted Patent B2
US 12,269,896 · App. 17/975,508 · Granted Apr 8, 2025

Antibodies specific for GUCY2c and uses thereof

Inventors: Chew Shun Chang (Athens, GA); Gurkan Guntas (Harvard, MA); Madan Katragadda (Acton, MA); Divya Mathur (Scarsdale, NY); Adam Reid Root (Newbury, MA); Lidia Mosyak (Newton, MA); Edward Roland Lavallie (Gilmanton, NH)
Assignee: PFIZER INC.
C07K16/40A61P35/00A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,269,896
App. No.
17/975,508
Granted
Apr 8, 2025
Kind
B2
Abstract

The present invention provides novel antibodies that specifically bind to GUCY2c and uses thereof in the treatment of cancer. The present invention further provides novel bispecific antibodies comprising such antibodies and uses thereof in the treatment of cancer.

Claims (55)

1. An antibody which specifically binds to guanylyl cyclase C (GUCY2c), wherein the antibody comprises:

a. a heavy chain variable (VH) region comprising a VH complementarity determining region one (VH CDR1), a VH complementarity determining region two (VH CDR2), and a VH complementarity determining region three (VH CDR3) of the VH sequence shown in SEQ ID NO: 11, and a light chain variable (VL) region comprising a VL complementarity determining region one (VL CDR1), a VL complementarity determining region two (VL CDR2), and a VL complementarity determining region three (VL CDR3) of the VL sequence shown in SEQ ID NO: 92;

b. a VH region comprising a VH CDR1, a VH CDR2 and a VH CDR3 of the VH sequence shown in SEQ ID NO: 19, and a VL region comprising a VL CDR1, a VL CDR2 and a VL CDR3 of the VL sequence shown in SEQ ID NO: 100;

c. a VH region comprising a VH CDR1, a VH CDR2 and a VH CDR3 of the VH sequence shown in SEQ ID NO: 26, and a VL region comprising a VL CDR1, a VL CDR2 and a VL CDR3 of the VL sequence shown in SEQ ID NO: 106;

d. a VH region comprising a VH CDR1, a VH CDR2 and a VH CDR3 of the VH sequence shown in SEQ ID NO: 33, and a VL region comprising a VL CDR1, a VL CDR2 and a VL CDR3 of the VL sequence shown in SEQ ID NO: 112;

e. a VH region comprising a VH CDR1, a VH CDR2 and a VH CDR3 of the VH sequence shown in SEQ ID NO: 41, and a VL region comprising a VL CDR1, a VL CDR2 and a VL CDR3 of the VL sequence shown in SEQ ID NO: 119;

f. a VH region comprising a VH CDR1, a VH CDR2 and a VH CDR3 of the VH sequence shown in SEQ ID NO: 48, and a VL region comprising a VL CDR1, a VL CDR2 and a VL CDR3 of the VL sequence shown in SEQ ID NO: 125;

g. a VH region comprising a VH CDR1, a VH CDR2 and a VH CDR3 of the VH sequence shown in SEQ ID NO: 52, and a VL region comprising a VL CDR1, a VL CDR2 and a VL CDR3 of the VL sequence shown in SEQ ID NO: 129;

h. a VH region comprising a VH CDR1, a VH CDR2 and a VH CDR3 of the VH sequence shown in SEQ ID NO: 57, and a VL region comprising a VL CDR1, a VL CDR2 and a VL CDR3 of the VL sequence shown in SEQ ID NO: 134;

i. a VH region comprising a VH CDR1, a VH CDR2 and a VH CDR3 of the VH sequence shown in SEQ ID NO: 60, and a VL region comprising a VL CDR1, a VL CDR2 and a VL CDR3 of the VL sequence shown in SEQ ID NO: 136;

j. a VH region comprising a VH CDR1, a VH CDR2 and a VH CDR3 of the VH sequence shown in SEQ ID NO: 62, and a VL region comprising a VL CDR1, a VL CDR2 and a VL CDR3 of the VL sequence shown in SEQ ID NO: 137;

k. a VH region comprising a VH CDR1, a VH CDR2 and a VH CDR3 of the VH sequence shown in SEQ ID NO: 65, and a VL region comprising a VL CDR1, a VL CDR2 and a VL CDR3 of the VL sequence shown in SEQ ID NO: 140;

l. a VH region comprising a VH CDR1, a VH CDR2 and a VH CDR3 of the VH sequence shown in SEQ ID NO: 67, and a VL region comprising a VL CDR1, a VL CDR2 and a VL CDR3 of the VL sequence shown in SEQ ID NO: 145;

m. a VH region comprising a VH CDR1, a VH CDR2 and a VH CDR3 of the VH sequence shown in SEQ ID NO: 69, and a VL region comprising a VL CDR1, a VL CDR2 and a VL CDR3 of the VL sequence shown in SEQ ID NO: 147;

n. a VH region comprising a VH CDR1, a VH CDR2 and a VH CDR3 of the VH sequence shown in SEQ ID NO: 71, and a VL region comprising a VL CDR1, a VL CDR2 and a VL CDR3 of the VL sequence shown in SEQ ID NO: 152; or

o. a VH region comprising a VH CDR1, a VH CDR2 and a VH CDR3 of the VH sequence shown in SEQ ID NO: 73, and a VL region comprising a VL CDR1, a VL CDR2 and a VL CDR3 of the VL sequence shown in SEQ ID NO: 147.

2. The antibody of claim 1 , wherein

a. the VH region comprises a VH CDR1 comprising a sequence shown in SEQ ID NO: 12, a VH CDR2 comprising a sequence shown in SEQ ID NO: 13, and a VH CDR3 comprising a sequence shown in SEQ ID NO: 14, and the VL region comprises a VL CDR1 comprising a sequence shown in SEQ ID NO: 93, a VL CDR2 comprising a sequence shown in SEQ ID NO: 94, and a VL CDR3 comprising a sequence shown in SEQ ID NO: 95;

b. the VH region comprises a VH CDR1 comprising a sequence shown in SEQ ID NO: 20, a VH CDR2 comprising a sequence shown in SEQ ID NO: 21, and a VH CDR3 comprising a sequence shown in SEQ ID NO: 22, and the VL region comprises a VL CDR1 comprising a sequence shown in SEQ ID NO: 101, a VL CDR2 comprising a sequence shown in SEQ ID NO: 102, and a VL CDR3 comprising a sequence shown in SEQ ID NO: 95;

c. the VH region comprises a VH CDR1 comprising a sequence shown in SEQ ID NO: 27, a VH CDR2 comprising a sequence shown in SEQ ID NO: 28, and a VH CDR3 comprising a sequence shown in SEQ ID NO: 29, and the VL region comprises a VL CDR1 comprising a sequence shown in SEQ ID NO: 107, a VL CDR2 comprising a sequence shown in SEQ ID NO: 108, and a VL CDR3 comprising a sequence shown in SEQ ID NO: 109;

d. the VH region comprises a VH CDR1 comprising a sequence shown in SEQ ID NO: 34, a VH CDR2 comprising a sequence shown in SEQ ID NO: 35, and a VH CDR3 comprising a sequence shown in SEQ ID NO: 36, and the VL region comprises a VL CDR1 comprising a sequence shown in SEQ ID NO: 113, a VL CDR2 comprising a sequence shown in SEQ ID NO: 114, and a VL CDR3 comprising a sequence shown in SEQ ID NO: 115;

e. the VH region comprises a VH CDR1 comprising a sequence shown in SEQ ID NO: 42, a VH CDR2 comprising a sequence shown in SEQ ID NO: 43, and a VH CDR3 comprising a sequence shown in SEQ ID NO: 44, and the VL region comprises a VL CDR1 comprising a sequence shown in SEQ ID NO: 120, a VL CDR2 comprising a sequence shown in SEQ ID NO: 78, and a VL CDR3 comprising a sequence shown in SEQ ID NO: 121;

f. the VH region comprises a VH CDR1 comprising a sequence shown in SEQ ID NO: 12, a VH CDR2 comprising a sequence shown in SEQ ID NO: 53, and a VH CDR3 comprising a sequence shown in SEQ ID NO: 14, and the VL region comprises a VL CDR1 comprising a sequence shown in SEQ ID NO: 93, a VL CDR2 comprising a sequence shown in SEQ ID NO: 94, and a VL CDR3 comprising a sequence shown in SEQ ID NO: 95;

g. the VH region comprises a VH CDR1 comprising a sequence shown in SEQ ID NO: 27, a VH CDR2 comprising a sequence shown in SEQ ID NO: 66, and a VH CDR3 comprising a sequence shown in SEQ ID NO: 29, and the VL region comprises a VL CDR1 comprising a sequence shown in SEQ ID NO: 107, a VL CDR2 comprising a sequence shown in SEQ ID NO: 141, and a VL CDR3 comprising a sequence shown in SEQ ID NO: 142;

h. the VH region comprises a VH CDR1 comprising a sequence shown in SEQ ID NO: 27, a VH CDR2 comprising a sequence shown in SEQ ID NO: 68, and a VH CDR3 comprising a sequence shown in SEQ ID NO: 29, and the VL region comprises a VL CDR1 comprising a sequence shown in SEQ ID NO: 107, a VL CDR2 comprising a sequence shown in SEQ ID NO: 146, and a VL CDR3 comprising a sequence shown in SEQ ID NO: 142;

i. the VH region comprises a VH CDR1 comprising a sequence shown in SEQ ID NO: 27, a VH CDR2 comprising a sequence shown in SEQ ID NO: 70, and a VH CDR3 comprising a sequence shown in SEQ ID NO: 29, and the VL region comprises a VL CDR1 comprising a sequence shown in SEQ ID NO: 148, a VL CDR2 comprising a sequence shown in SEQ ID NO: 149, and a VL CDR3 comprising a sequence shown in SEQ ID NO: 142;

j. the VH region comprises a VH CDR1 comprising a sequence shown in SEQ ID NO: 27, a VH CDR2 comprising a sequence shown in SEQ ID NO: 72, and a VH CDR3 comprising a sequence shown in SEQ ID NO: 29, and the VL region comprises a VL CDR1 comprising a sequence shown in SEQ ID NO: 153, a VL CDR2 comprising a sequence shown in SEQ ID NO: 141, and a VL CDR3 comprising a sequence shown in SEQ ID NO: 154; or

k. the VH region comprises a VH CDR1 comprising a sequence shown in SEQ ID NO: 74, a VH CDR2 comprising a sequence shown in SEQ ID NO: 75, and a VH CDR3 comprising a sequence shown in SEQ ID NO: 29, and the VL region comprises a VL CDR1 comprising a sequence shown in SEQ ID NO: 148, a VL CDR2 comprising a sequence shown in SEQ ID NO: 149, and a VL CDR3 comprising a sequence shown in SEQ ID NO: 142.

3. The antibody of claim 1 , wherein:

a. the VH region comprises (i) a VH CDR1 comprising the sequence of SEQ ID NO: 74 or 259; (ii) a VH CDR2 comprising the sequence of SEQ ID NO: 75 or 267; and iii) a VH CDR3 comprising the sequence of SEQ ID NO: 29; and

b. the VL region comprises (i) a VL CDR1 comprising the sequence of SEQ ID NO: 148; (ii) a VL CDR2 comprising the sequence of SEQ ID NO: 149; and (iii) a VL CDR3 comprising the sequence of SEQ ID NO: 142.

4. The antibody of claim 1 , wherein:

a. the VH region comprises a sequence of SEQ ID NO: 11, and the VL region comprises a sequence of SEQ ID NO: 92;

b. the VH region comprises a sequence of SEQ ID NO: 19, and the VL region comprises a sequence of SEQ ID NO: 100;

c. the VH region comprises a sequence of SEQ ID NO: 26, and the VL region comprises a sequence of SEQ ID NO: 106;

d. the VH region comprises a sequence of SEQ ID NO: 33, and the VL region comprises a sequence of SEQ ID NO: 112;

e. the VH region comprises a sequence of SEQ ID NO: 41, and the VL region comprises a sequence of SEQ ID NO: 119;

f. the VH region comprises a sequence of SEQ ID NO: 48, and the VL region comprises a sequence of SEQ ID NO: 125;

g. the VH region comprises a sequence of SEQ ID NO: 52, and the VL region comprises a sequence of SEQ ID NO: 129;

h. the VH region comprises a sequence of SEQ ID NO: 57, and the VL region comprises a sequence of SEQ ID NO: 134;

i. the VH region comprises a sequence of SEQ ID NO: 60, and the VL region comprises a sequence of SEQ ID NO: 136;

j. the VH region comprises a sequence of SEQ ID NO: 62, and the VL region comprises a sequence of SEQ ID NO: 137;

k. the VH region comprises a sequence of SEQ ID NO: 65, and the VL region comprises a sequence of SEQ ID NO: 140;

l. the VH region comprises a sequence of SEQ ID NO: 67, and the VL region comprises a sequence of SEQ ID NO: 145;

m. the VH region comprises a sequence of SEQ ID NO: 69, and the VL region comprises a sequence of SEQ ID NO: 147;

n. the VH region comprises a sequence of SEQ ID NO: 71, and the VL region comprises a sequence of SEQ ID NO: 152; or

o. the VH region comprises a sequence of SEQ ID NO: 73, and the VL region comprises a sequence of SEQ ID NO: 147.

5. The antibody of claim 1 , wherein the VH region comprises the sequence of SEQ ID NO: 73; and wherein the VL region comprises the sequence of SEQ ID NO: 147.

6. The antibody of claim 1 , wherein the VH region comprises the sequence of SEQ ID NO: 73, or a variant thereof with one or several conservative amino acid substitutions in residues that are not within a CDR region; and/or wherein the VL region comprises the sequence of SEQ ID NO: 147, or a variant thereof with one or several conservative amino acid substitutions in amino acids that are not within a CDR region.

7. The antibody of claim 1 wherein the antibody is a humanized antibody.

8. A polynucleotide comprising a nucleotide sequence encoding the antibody of claim 1 .

9. A vector comprising the polynucleotide of claim 8 .

10. A host cell comprising the vector of claim 9 .

11. A method of producing an antibody comprising culturing the host cell of claim 10 , under conditions that result in production of the antibody of claim 1 and purifying the antibody from the culture supernatant.

12. A pharmaceutical composition comprising the antibody of claim 1 .

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →